UL Launches Medical IoT Battery SOH Transparency Certification Pilot

On May 5, 2026, UL Solutions announced the launch of its ‘Medical IoT Battery State-of-Health (SOH) Transparency’ certification pilot program — a new initiative requiring real-time, encrypted reporting of battery health parameters for medical-grade IoT devices such as continuous glucose monitors and portable ultrasound systems. This development signals heightened scrutiny of battery data integrity in regulated healthcare hardware, with implications for PCBA solution providers, medical device OEMs, and global supply chain stakeholders operating at the intersection of battery safety, cybersecurity, and regulatory compliance.

Event Overview

UL Solutions initiated the ‘Medical IoT Battery SOH Transparency’ certification pilot on May 5, 2026. The program mandates that lithium batteries used in medical IoT devices must embed algorithms capable of continuously calculating and securely transmitting key State-of-Health (SOH) metrics — including remaining capacity, internal resistance degradation rate, and cycle count. Two China-based PCBA solution providers have been accepted into the inaugural pilot cohort, marking the first formal inclusion of Chinese medical hardware suppliers in UL’s international battery data trust framework.

Industries Affected

PCBA Solution Providers (Medical Hardware Tier-2 Suppliers)

These firms are directly impacted because they design and integrate battery management subsystems into medical IoT end products. The pilot requires embedded algorithmic SOH computation and secure telemetry — capabilities beyond standard BMS firmware implementation. Impact includes increased validation burden, need for cryptographic module integration, and alignment with UL’s upcoming test protocols for data authenticity and tamper resistance.

Medical Device OEMs (Especially Those Outsourcing Battery Subsystems)

OEMs relying on third-party PCBA vendors face downstream compliance risk if their suppliers lack SOH transparency readiness. As UL’s certification gains traction, product registration timelines, FDA premarket submissions (e.g., 510(k), De Novo), and EU MDR technical documentation may increasingly reference battery data traceability as part of reliability and cybersecurity assessments.

Battery Component Manufacturers & Module Integrators

Suppliers of cells, protection circuits, or battery packs must now consider whether their offerings support deterministic SOH parameter derivation — not just voltage/current sensing. The pilot emphasizes algorithmic accuracy and calibration traceability, shifting emphasis from passive component specs toward software-defined health modeling capabilities.

Regulatory & Certification Support Service Providers

Firms offering UL liaison, FDA submission support, or IEC 62304/62443 compliance consulting will see rising demand for cross-domain expertise bridging battery electrochemistry, embedded firmware security, and medical device quality system requirements (e.g., ISO 13485).

What Stakeholders Should Monitor and Do Now

Track official scope expansion and timeline announcements

UL has labeled this a ‘pilot’, meaning formal criteria, test methods, and certification fees remain unpublished. Stakeholders should monitor UL’s official communications for updates on eligibility criteria, validation requirements (e.g., algorithm audit, encryption standards), and potential extension to non-pilot participants after mid-2026.

Assess SOH data architecture in current and near-term medical IoT designs

Review whether existing battery firmware supports deterministic, calibrated SOH calculation — especially internal resistance tracking and aging model traceability. Note: Generic fuel-gauge IC outputs are unlikely to satisfy UL’s transparency requirement unless augmented with validated, vendor-documented algorithms.

Distinguish between regulatory signal and enforceable requirement

This is not yet a mandatory standard or regulatory mandate. It is a voluntary pilot aligned with emerging expectations under IEC 62366-2 (usability), IEC 62443 (cybersecurity), and FDA guidance on software in medical devices. Its influence lies in precedent-setting — not immediate enforcement.

Engage early with UL-accredited labs and PCBA partners on data pipeline design

For companies planning new product introductions in 2027–2028, initiating dialogue with testing labs on secure telemetry architecture (e.g., TLS 1.3 over BLE, attestation mechanisms) and collaborating with PCBA vendors on algorithm documentation frameworks can reduce future rework risk.

Editorial Perspective / Industry Observation

Observably, this pilot reflects UL’s strategic shift from certifying static hardware safety to validating dynamic, software-mediated trustworthiness of critical subsystems. Analysis shows it is less about battery chemistry per se and more about establishing verifiable, auditable data provenance — a capability increasingly demanded across AI-integrated and remote-monitoring medical devices. From an industry perspective, it functions primarily as a forward-looking signal: one that anticipates tightening interoperability and transparency expectations in next-generation medical IoT, rather than enforcing immediate change. Continued observation is warranted, particularly regarding whether SOH transparency becomes a de facto prerequisite for market access in high-regulation jurisdictions.

In summary, UL’s Medical IoT Battery SOH Transparency pilot introduces a new dimension of accountability for battery health data in regulated medical devices. Its significance lies not in immediate compliance deadlines, but in signaling an evolving baseline for trust — where battery performance is no longer assessed solely through lab tests, but through continuous, authenticated digital evidence. For now, it is best understood as an early indicator of how functional safety and cybersecurity requirements are converging in medical hardware supply chains — not as an operational mandate, but as a strategic inflection point.

Source: UL Solutions official announcement (May 5, 2026). Note: Certification criteria, test methodology, and commercial rollout timeline remain pending and subject to further public disclosure.